[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-phospholipid-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-phospholipid-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100650095","autoimmune-hemolytic-anemia-and-its-clinical-implication-on-antiphospholipid-syndrome-100650095",false,"NCT07743242","Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients with anemia consistant with hemolysis.\n* Patient diagnosed with antiphospholipid syndrome.\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Other causes of anemia than autoimmune hemolysis.","ALL","18 Years",{"count":18,"type":19},230,"ESTIMATED","INTERVENTIONAL",[22],"NA","AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and\u002For obstetric morbidity with persistent antiphospholipid antibodies (aPL).",[25],"Anti Phospholipid Syndrome",[27],"AIHA","RECRUITING","2026-08-05",{"date":31,"type":32},"2026-08-10","ACTUAL",{"date":34,"type":32},"2026-06-05",{"date":36,"type":19},"2028-04-15",{"name":38,"class":39},"New Valley University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100456932","chinese-antiphospholipid-syndrome-cohort-collaborative-networks-100456932","NCT05230017","Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks","CAPSTONE","Inclusion Criteria:\n\n* The presence of one or more of the antiphospholipid antibodies (aPL) tested according to the 2006 Sapporo APS clasification criteria, on two or more occasions at least 12 weeks apart:\n\nExclusion Criteria:\n\n* Patients refuse to participate;\n* Unable to be followed.",{"count":49,"type":19},2000,"OBSERVATIONAL","Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (aPLs). However, large-scale research on general population with persistent aPLs has been lacking. This project proposes to establish the first multicenter cohort of patients with persistently positive aPLs in China and conduct a comprehensive clinical phenotyping study. Based on traditional phenotypes of thrombotic and pregnancy events, the focus will be on extra-standard clinical phenotypes and prospective assessment of event risk and prognosis in aPL-positive population. A prospective analysis of extra-standard antibodies will also be conducted to recommend detection criteria for extra-standard antibody application in China and to assess their clinical significance.",[25],[54],"anti-phospholipid antibody","2024-07-29",{"date":57,"type":32},"2024-07-30",{"date":59,"type":32},"2022-10-01",{"date":61,"type":19},"2026-12-01",{"name":63,"class":39},"Peking Union Medical College Hospital",18]